On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
Pearce IP BioBlast® for the period 22 December 2024 to 17 January 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the period 22...